Group 1 - The core product of the company includes peptide synthesis reagents and general molecular building blocks, primarily used for the chemical synthesis of amide bonds [2] - The company's operations are influenced by various factors such as downstream demand fluctuations, price volatility, industry competition, and capacity layout [2]

证券日报网讯 12月10日，昊帆生物在互动平台回答投资者提问时表示，公司始终坚持以稳健经营、持 续创新和规范治理为基础，致力于为股东创造长期价值。在信息披露合规的前提下，公司积极通过多种 渠道加强与资本市场的沟通交流。公司将在市值管理方面持续优化。 （文章来源：证券日报） ...

Group 1 - The core patent of Semaglutide will expire in March next year, which raises questions about its potential positive impact on the company's operations [2] - Haofan Bio (301393.SZ) stated that its main products include peptide synthesis reagents and general molecular building blocks, primarily used for the chemical synthesis of amide bonds [2] - The company's operations are influenced by various factors, including fluctuations in downstream demand, price volatility, industry competition, and capacity layout [2]

Core Viewpoint - The company Huai'an Haofan is developing a new production base with a planned annual capacity of 5,130 tons for various peptide synthesis reagents, with the first phase involving the construction of five workshops by 2026 [1] Group 1: Production Capacity and Products - The new project will produce a total of 34 types of products, with specific capacities including: 2,500 tons of condensation reagents, 800 tons of protective reagents, 100 tons of green N-amino reagents, 400 tons of chiral racemic inhibitors, 20 tons of protein reagents, 600 tons of condensation activation aids, 400 tons of nucleotide reagents, 20 tons of peptide crosslinking agents, and 290 tons of protective amino acids [1]

（记者 王晓波） 每经AI快讯，有投资者在投资者互动平台提问：请问公司淮安项目主体建筑部分目前是否结顶？ 昊帆生物（301393.SZ）12月10日在投资者互动平台表示，淮安昊帆生产基地共规划10个生产车间，为 保障产能建设安全、快速、有序推进，公司拟分期建设生产线，计划在2026年先建设5个车间的生产线 并申请试生产，后续依据市场需求和产品布局开始规划和建设其他车间的生产线。目前该项目正在按照 既定规划有序推进。上述时间为管理层根据目前建设进展和现场情况所作的估计，项目实施面临各方面 不确定性因素，请投资者注意投资风险。为保证信息披露的公平性，公司将在定期报告和临时公告中披 露关于产能建设的重要进展。 ...

Group 1 - The core patent for Semaglutide will expire in March next year, which may have a positive impact on the company's operations [1] - Haofan Bio (301393.SZ) stated that its main products include peptide synthesis reagents and general molecular building blocks, primarily used for the chemical synthesis of amide bonds [1] - The company's operations are influenced by various factors including downstream demand fluctuations, price volatility, industry competition, and capacity layout [1]

Market Overview - The biopharmaceutical sector experienced a decline of 1.72% on December 2, with Aopumai leading the drop [1] - The Shanghai Composite Index closed at 3897.71, down 0.42%, while the Shenzhen Component Index closed at 13056.7, down 0.68% [1] Individual Stock Performance - Dongbao Bio (300239) closed at 5.80, up 1.05% with a trading volume of 93,700 shares and a transaction value of 53.99 million yuan [1] - Aopumai (688293) saw a significant drop of 8.01%, closing at 50.32 with a trading volume of 33,400 shares and a transaction value of 171 million yuan [2] - Other notable declines included Kanghong Pharmaceutical (002773) down 3.78% and Watson Bio (300142) down 3.17% [2] Capital Flow Analysis - The biopharmaceutical sector experienced a net outflow of 456 million yuan from institutional investors, while retail investors saw a net inflow of 270 million yuan [2] - Notable stocks with significant capital inflows included He Yuan Bio (688765) with a net inflow of 17.69 million yuan from institutional investors [3] - Conversely, stocks like Rongchang Bio (688331) and Shenzhou Cell (688520) also saw mixed capital flows, indicating varied investor sentiment [3]

Core Viewpoint - Haofan Bio (301393.SZ) announced changes in the use of raised funds and project completion timelines due to external policy changes and operational needs [1] Group 1: Fund Usage Changes - The project "Suzhou Haofan Bio Co., Ltd. 100kg/year peptide and protein reagent R&D and production and headquarters construction project (Phase I)" has reached a usable state, and the remaining funds will be used to supplement working capital [1] - The company plans to change the use of a total of 49,696.68 million yuan of raised funds from the "Anhui Haofan peptide reagent and pharmaceutical intermediates construction project" and "peptide and protein reagent R&D platform construction project" to the "Huaian Haofan production base construction project" [1] - The remaining funds after the changes will be used to supplement working capital, with the net amount being cash management income minus handling fees [1] Group 2: Project Completion and Timeline Adjustments - The "Anhui Haofan peptide reagent and pharmaceutical intermediates construction project" and "peptide and protein reagent R&D platform construction project" are proposed to be completed [1] - The timeline for the "Huaian Haofan production base construction project" is extended to December 2028 to ensure safe, rapid, and orderly capacity construction [1]

Core Points - Haofan Bio (301393.SZ) announced the approval of changes in the use of raised funds and the completion of certain fundraising projects during its board and supervisory meetings [1] Group 1: Fund Utilization Changes - The project "Suzhou Haofan Bio Co., Ltd. 100kg/year peptide and protein reagent R&D and production and headquarters construction project (Phase I)" has reached a state of intended use, and the remaining funds will be used to supplement working capital [1] - Due to external policy changes and the current operational needs, the company plans to change the use of a total of 49,696.68 million yuan of raised funds from the "Anhui Haofan peptide reagent and pharmaceutical intermediates construction project" and "peptide and protein reagent R&D platform construction project" to the "Huaian Haofan production base construction project" [1] - The "Anhui Haofan peptide reagent and pharmaceutical intermediates construction project" and "peptide and protein reagent R&D platform construction project" are proposed to be completed, with the remaining funds after the changes being used to supplement working capital [1] Group 2: Project Timeline Adjustments - To ensure the safe, rapid, and orderly advancement of capacity construction, the company has decided to phase the construction of the production line for the Huaian Haofan production base, extending the timeline to reach the intended use state until December 2028 [1]

Group 1 - The company announced the internal appointment changes, with Mr. Chen Yifan no longer serving as the head of the internal audit department, and Ms. Lu Liyan appointed as the new head [1] - For the year 2024, the company's revenue composition is entirely from the manufacturing of chemical raw materials and chemical products, accounting for 100.0% [1] - The current market capitalization of the company is 5.4 billion yuan [1]